JAG1

Across TCGA pan-cancer cohorts, JAG1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JAG1 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher JAG1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated JAG1 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where JAG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.357	0.931	.006	27	view →
CCRCC	OS	Quartile	All	0.820	0.985	.033	10	view →
GBM	OS	Tertile	All	0.636	0.383	.030	4	view →
PDAC	OS	Quartile	II,III,IV	0.980	0.714	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JAG1–LUAD (OS)

Open the LUAD breakdown →